- Home
- CRIS vs COCH Comparison
CRIS vs COCH Comparison
Compare CRIS & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- COCH
- Stock Information
- Founded
- CRIS 2000
- COCH 1995
- Country
- CRIS United States
- COCH United States
- Employees
- CRIS N/A
- COCH N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- COCH Blank Checks
- Sector
- CRIS Health Care
- COCH Finance
- Exchange
- CRIS Nasdaq
- COCH Nasdaq
- Market Cap
- CRIS 22.9M
- COCH 25.2M
- IPO Year
- CRIS 2000
- COCH N/A
- Fundamental
- Price
- CRIS $1.77
- COCH $1.30
- Analyst Decision
- CRIS Strong Buy
- COCH Strong Buy
- Analyst Count
- CRIS 2
- COCH 2
- Target Price
- CRIS $16.50
- COCH $9.25
- AVG Volume (30 Days)
- CRIS 75.9K
- COCH 789.8K
- Earning Date
- CRIS 11-13-2025
- COCH 11-13-2025
- Dividend Yield
- CRIS N/A
- COCH N/A
- EPS Growth
- CRIS N/A
- COCH N/A
- EPS
- CRIS N/A
- COCH N/A
- Revenue
- CRIS $11,405,000.00
- COCH $222,000.00
- Revenue This Year
- CRIS $1.41
- COCH $4.27
- Revenue Next Year
- CRIS $7.46
- COCH $23.37
- P/E Ratio
- CRIS N/A
- COCH N/A
- Revenue Growth
- CRIS 12.24
- COCH N/A
- 52 Week Low
- CRIS $1.02
- COCH $1.06
- 52 Week High
- CRIS $6.44
- COCH $3.99
- Technical
- Relative Strength Index (RSI)
- CRIS 52.53
- COCH 47.84
- Support Level
- CRIS $1.63
- COCH $1.23
- Resistance Level
- CRIS $1.95
- COCH $1.37
- Average True Range (ATR)
- CRIS 0.14
- COCH 0.09
- MACD
- CRIS 0.02
- COCH 0.02
- Stochastic Oscillator
- CRIS 45.59
- COCH 74.00
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.